JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
JOHNSON & JOHNSON
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026
$253.79−1.77 (-0.69%)
Close on Oct 19, 2026
- Market cap
- $619.27B
- P/E (TTM)
- 29.4
- Dividend yield
- 2.03%
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
67.9%+2.3 pts over 5 years
Operating margin
–
Net margin
28.5%+10.6 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +6.0% | +5.6% | +2.7% | +3.0% | |
| Gross profit | +4.2% | +4.9% | +3.4% | +2.8% | |
| Net income | +90.6% | +14.3% | +12.7% | +5.7% | |
| EPS, diluted | +90.5% | +17.9% | +14.9% | +7.2% | |
| Free cash flow | -0.7% | +4.7% | -0.5% | +2.0% | |
| Dividend per share | +4.7% | +4.9% | +5.2% | +5.7% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | 35.0% | |
| Return on assets | 12.0% | 8.8% | 14.1% | |
| Current ratio | 2.47 | 1.21 | 1.03 | |
| Debt to equity | – | – | 0.59 | |
| Inventory turnover | 2.7× | 3.1× | 2.3× | |
| Capex to revenue | 4.5% | 4.1% | 5.1% | |
| Diluted shares | 2.79B | 2.67B | 2.43B |
Where the cash went
Fiscal 2021 to 2025, five years combined
Johnson & Johnson generated $116.19B from operations and spent $44.39B on capital expenditure, dividends and share buybacks. 48% of that went back into the business.
Generated
$116.19B
Used
$44.39B
Capital expenditure$21.46B48%Dividends$00%Share buybacks$22.93B52%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin28.5%
×Asset turnover0.50×
×Equity multiplier2.48×
=Return on equity, FY202535.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 28.5% | 0.50× | 2.48× | 35.0% |
| FY2024 | 15.8% | 0.51× | 2.48× | 20.1% |
| FY2023 | 41.3% | 0.48× | 2.44× | 48.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$26.80B
- Cash generatingOperating cash flow above zero$24.53B
- Return on assets improvedROA up on the prior year8.4% → 14.9%
- Earnings backed by cashOperating cash flow above net income$24.53B vs $26.80B
- Less leverageLong-term debt to assets fell17.0% → 19.8%
- Better liquidityCurrent ratio rose1.11 → 1.03
- No dilutionShare count did not rise2.43B → 2.43B
- Gross margin improvedGross margin up on the prior year69.07% → 67.88%
- More efficientAsset turnover rose0.53 → 0.52